Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a "role model" for precision cancer medicine, with several important therapeutic breakthroughs occurring during 2015. These advances have occurred primarily in the immunotherapy field and in treatments directed against tumors harboring specific oncogenic drivers. Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for patients with lung cancer who have advanced disease have occurred. The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of lung cancer during the past year.

Additional Metadata
Keywords Adjuvant chemotherapy, Biomarkers, Cancer prevention, Gene mutations, Immunotherapy, Lung cancer, Master protocols, Pathology, Radiotherapy, Screening, Smoking cessation, Staging, Surgery, Targeted therapy, Value of therapy
Persistent URL dx.doi.org/10.1016/j.jtho.2016.03.012, hdl.handle.net/1765/84636
Journal Journal of Thoracic Oncology
Citation
Tsao, A.S, Scagliotti, G.V, Bunn, P.A, Carbone, D.P, Warren, G.W, Bai, C, … Pass, H.I. (2016). Scientific advances in lung cancer 2015. Journal of Thoracic Oncology (Vol. 11, pp. 613–638). doi:10.1016/j.jtho.2016.03.012